Micromet, Inc. to Webcast Panel Session at the 2006 RBC Capital Markets Healthcare Conference

Market Wire, December, 2006

Carlsbad, CA - December 12, 2006 - Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, announced today that Christian Itin, President & Chief Executive Officer of Micromet, will participate on the "New Antibody Technology" panel at the 2006 RBC Capital Markets Healthcare Conference on Thursday, December 14th, 2006 at 01:00 p.m. Eastern time. The conference will be held at the Westin New York at Times Square in New York City.

The 55-minute panel session will be webcast live on December 14th and will be accessible through Micromet's website at http://www.micromet-inc.com . A replay of the panel session will also be available via the website until January 14th, 2007.

About Micromet, Inc. ( www.micromet-inc.com )

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. Adecatumumab (MT201) is a recombinant human monoclonal antibody which targets EpCAM expressing tumors with which Micromet has completed two phase 2 clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. MT103 (MEDI-538), which is the first product candidate based on the novel a BiTE® product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkins lymphoma in conjunction with MedImmune. The BiTE® product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. Micromet has established collaborations with MedImmune and Serono.

About BiTE®

BiTE® molecules are a new generation of antibody-based drugs designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells. BiTE® molecules represent a new therapeutic approach to cancer therapy. BiTE® molecules have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses mediate the delivery of cytotoxic proteins called perforin and granzymes from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE® molecules, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE® molecules at very low concentrations and at very low ratios of T cells to target cells. Through the killing process, T cells start to proliferate at the site of the tumor, which leads to an increased number of T cells at the site of attack improving the ratio of T cells to tumor cells.

Contact Information:

Investors: Ines-Regina Buth
 1 760-494-4235 (US)
 49 (0)89 895277 221 (Europe)
 ines.buth@micromet-inc.com 

Media Europe: Evelyn Wolf
 49 (0)89 895277 220
 evelyn.wolf@micromet-inc.com 

Media US: Susan Noonan
(212) 966-3650
 susan@sanoonan.com 

Copyright © Hugin ASA 2006. All rights reserved.